Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times

Clinical Microbiology and Infection

Volumn 9, Issue 5, 2003, Pages 370-379

  Spencker, F B ^a   Staber, L ^a   Lietz, T ^a   Schille, R ^a   Rodloff, A C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antibiotic resistance; Cystic fibrosis; Minimal inhibitory concentrations (MICs); Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; CYSTIC FIBROSIS; DILUTION; HUMAN; INFANT; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; RESPIRATORY TRACT INFECTION;

BACTERIA (MICROORGANISMS); PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0037532733     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00534.x     Document Type: Article

References (22)

1. Kerem BS, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-80.
2. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid. Pseudomonas Aeruginosa Burkholderia Cepacia Microbiol Rev 1996; 60: 539-74.
3. Pedersen SS, Høiby N, Espersen F, Kock C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 1992; 47: 6-13.
4. Fyfe JAM, Harris G, Govan JRW. Revised pyocin typing method for Pseudomonas aeruginosa. J Clin Microbiol 1984; 20: 47-50.
5. Spencker F-B, Haupt S, Claros MC, et al. Epidemiologic characterization of Pseudomonas aeruginosa in patients with cystic fibrosis. Clin Microbiol Infect 2000; 6: 600-7.
6. DIN. Deutsches Institut für Normung e. V. Medizinische Mikrobiologie und Immunologie, Diagnostische Verfahren. Berlin-Wien-Zürich: 3 Auflage. Beuth-Verlag, 2000: 215-72.
7. Ciofu O, Giwercman B, Pedersen SS, Hoiby N. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS 1994; 102: 674-80.
8. Mouton JW, Hollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993; 31: 919-26.
9. Taccetti G, Campana S, Marianelli L. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients. The results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology. Eur J Epidemiol 1999; 15: 85-8.
10. Shawar RM, MacLeod DL, Garber RL, et al. Activities of Tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 2877-80.
11. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-51.
12. Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients. comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Pediatr Infect Dis J 1997; 16: 572-8.
13. Jalal S, Ciofu O, Hoiby N, Gotho N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000; 44: 710-2.
14. Spencker F-B. Antibakterielle Aktivität von Meropenem in Vergleich mit sieben anderen Antibiotika gegenüber Stämmen von Pseudomonas aeruginosa, Stenotrophomonas maltophilia und Burkholderia cepacia isoliert von Kindern mit Mukoviszidose. Z Antimikr Antineoplast Chemother 1997; 15: 111-4.
15. Ballestro S, Fernandez-Rodriguez A, Villaverde R, Escobar H, Perez-Diaz JC, Baquero F. Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients. J Antimicrob Chemother 1996; 38: 39-45.
16. Chen HY, Livermore DM. In vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J Antimicrob Chemother 1994; 33: 949-58.
17. Bonfiglio G, Marchetti F. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams. Chemotherapy 2000; 46: 229-34.
18. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-82.
19. Elborn JS, Prescott RJ, Stack BHR, et al. Elective versus symptomatic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000; 55: 355-8.
20. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled Tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30.
21. Burns JL, van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179: 1190-6.
22. MacLeod DL, Nelson LE, Shawar RM, et al. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled Tobramycin treatment. J Infect Dis 2000; 181: 1180-4.